StreetInsider.com News Articles

Nuvation Bio Inc (NUVB) PT Raised to $20 at RBC Capital

Fri, 07 Aug 2026 07:29:56 -0400

RBC Capital analyst Leonid Timashev raised the price target on Nuvation Bio Inc (NYSE: NUVB) to $20.00 (from $19.00) while maintaining a Outperform rating.

Nuvation Bio Inc. (NUVB) Misses Q2 EPS by 3c

Thu, 06 Aug 2026 07:34:27 -0400

Nuvation Bio Inc. (NYSE: NUVB) reported Q2 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $31.69 million versus the consensus estimate of $26.69 million.

For earnings history and earnings-related data on Nuvation Bio Inc. (NUVB) click here.

Nuvation Bio posts $31.7M Q2 revenue, widens net loss to $62.8M

Thu, 06 Aug 2026 07:31:09 -0400

Nuvation Bio Inc. (NYSE: NUVB) reported total revenue of $31.7 million for the second quarter ended June 30, 2026, up from $4.8 million in the same period a year earlier, according to a company press release.

Net product revenue from U.S. sales of IBTROZI (taletrectinib), the company's ROS1 inhibitor for advanced non-small cell lung cancer, was $23.2 million, a 25% increase from the prior quarter. Collaboration and license agreements revenue was $8.5 million, compared with $3.6 million in Q2 2025. Approximately 160 new patients started on IBTROZI during the quarter, with about 85% classified as TKI-naïve, representing roughly 30% quarter-over-quarter growth

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)

IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year

~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting

Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma

Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:30:00 -0400

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI^® (taletrectinib)
IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the year
~85% of the approximately 160 new patients were TKI-naïve, representing QoQ growth of ~30% in this setting
Announced positive updated long-term Phase 2 data for safusidenib and significant expansion of clinical program to address broad spectrum of IDH1-mutant glioma
Robust balance sheet with cash, cash equivalents, and

Form 8-K Nuvation Bio Inc. For: Aug 06

Thu, 06 Aug 2026 07:30:00 -0400
si-local-file:///var/storage/secattach/20260806/26878821.html

Form 8-K Nuvation Bio Inc. For: Aug 06

Thu, 06 Aug 2026 07:30:00 -0400
si-local-file:///var/storage/secattach/20260806/26878821.html

Form 10-Q Nuvation Bio Inc. For: Jun 30

Thu, 06 Aug 2026 06:55:00 -0400
si-local-file:///var/storage/secattach/20260806/26878160.html

Form 10-Q Nuvation Bio Inc. For: Jun 30

Thu, 06 Aug 2026 06:55:00 -0400
si-local-file:///var/storage/secattach/20260806/26878160.html

Nuvation Bio to present taletrectinib subgroup data at WCLC and ESMO

Tue, 04 Aug 2026 08:01:20 -0400

Nuvation Bio Inc. (NYSE: NUVB) plans to present new subgroup analyses from its Phase 2 TRUST-I and TRUST-II studies of taletrectinib (Ibtrozi) at two upcoming medical conferences.
At the IASLC 2026 World Conference on Lung Cancer, scheduled for September 12–15 in Seoul, South Korea, Hidetoshi Hayashi of Kindai University Faculty of Medicine will present data on taletrectinib across key patient subgroups with ROS1-positive non-small cell lung cancer on September 15.
At the European Society of Medical Oncology Congress, running October 23–27 in Madrid, Spain, Maurice Pérol of Léon Bérard Cancer Center in Lyon, France, will present updated efficacy and safety data for

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Tue, 04 Aug 2026 08:00:00 -0400

Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroups
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new analyses of long-term Phase 2 TRUST-I and TRUST-II data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) taking place September 12–15, 2026, in Seoul, South Korea, and at the European Society of Medical Oncology Congress (ESMO)